Gee, it's slow, this one. It has moved from its low of 39c, though- up some 5%. it may move to 42c on Monday- that's the new ask price, and the Aussie futures are down by 17 points on Monday, so punters might be looking for a defensive stock with a cash possibility:
http://www.bloomberg.com/markets/stocks/futures
Of relative note, API have had a greater recovery than SIP, although they had the same Pfizer decision crash- I put this down to API recently responding with an update on deals with pharmacies. SIP could do the same... but will they?
There may be a share price increase leading up to Friday's decision on SIP's sale to Aspen- I'll stick my neck out and say this one will be a done deal. If not, we're stuffed. Actually, i'm uncertain as to why a vote is needed- I haven't seen that occur on trade deals or takeovers in the past. Anyone know why this one is necessary?
If the deal goes through Friday, we *should* get more SP growth. Capital gain + FF dividend = sweet. I'm still not sure why Lazard sold down... we'll probably never know, unless something left of field occurs and it all falls apart. We know that Orbis will be voting for the sale, as will Maple-Brown Abbott, presumably, or why would they buy in now?
Closure is near for this little saga. I'll still be hoping for 12c dividend, needle- i'm not so bullish as you. The Company still needs to continue as a going concern- franking credits notwithstanding (and Orbis can only lobby, but not decide the outcome). SIP also need to pay for the class action. 18c would be close to a 45% return. I'll stick with a 30% return hope. Still good buying for the risk-tolerant.
Add to My Watchlist
What is My Watchlist?